Dr Paul Daniel is a Senior Postdoctoral Research Fellow for the Hudson Monash Paediatric Precision Medicine Program at Hudson Institute

Dr Paul Daniel

  • Role: Postdoctoral Scientist

Dr Paul Daniel is a Senior Postdoctoral Research Fellow for the VPCC Next Generation Precision Medicine program.

After completing his PhD with Dr Theo Mantamadiotis at Melbourne University, Dr Daniel undertook a three year postdoctoral fellowship at McGill University in Canada, looking into therapeutic opportunities in adult Glioblastoma which emerge following exposure to chemotherapy.

At the conclusion of Dr Daniel’s time in Canada, he then joined Next Generation Precision Medicine, led by Professor Ron Firestein, where he is currently exploring paediatric central nervous system tumours and the capacity for targeted therapies to direct tumour evolution towards states with predictable vulnerabilities. His research involves use of clinically relevant in vitro and in vivo tumour models, such as patient derived cell lines and xenografts.

Selected publications

  • Sharifi S, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot M, Jean-Claude B,  Sabri S (2019) Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Clin Cancer Res 25:7594-7608.

  • Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim B (2019) Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 9:41.

  • *Chaddad A, *Daniel P, Sabri S, Desrosiers C, Abdulkarim B (2019). Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma. Cancers (Basel) pii:E1148. *co-first author.

  • Daniel PM, Filiz G, Brown DV, Christie M, Waring PM, Zhang Y, Haynes JM, Pouton C, Flanagan D, Vincan E, Johns TG, Montgomery K, Phillips WA, Mantamadiotis T (2018) PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein. Neuro Oncol 20:1344–1355.

  • Garnier D, Meehan B, Kislinger T, Daniel P, Sinha A, Abdulkarim B, Nakano I, Rak J (2018) Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol 20:236-248.

  • *Nguyen, H., *Daniel, P., Filiz, G., and Mantamadiotis, T. (2018). Investigating Neural Stem Cell and Glioma Stem Cell Self-renewal Potential Using Extreme Limiting Dilution Analysis (ELDA). Bio-protocol 8:e2991. *co-first author.

  • Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, Kountouri N, Ng W, Morokoff AP, Mantamadiotis T (2017) Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS One 12:e0172791.

  • Daniel PM, Filiz G, Mantamadiotis T (2016) Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling. Cell Death Dis 7:e2494.

  • Brown DV, Daniel PM, D’Abaco GM, Gogos A, Ng W, Morokoff AP, Mantamadiotis T (2015) Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6:6267–6280.

  • Daniel P, Filiz G, Brown DV, Hollande F, Gonzales M, D’Abaco G, Papalexis N, Phillips WA, Malaterre J, Ramsay RG, Mantamadiotis T (2014) Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis 3:e108.